공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

내분비 검사 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년)

Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 1005799
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


내분비 검사 시장 : 성장, 동향, COVID-19의 영향, 예측(2021-2026년) Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

내분비 검사 시장 규모는 2020년 91억 7,062만 달러로 평가되었으며, 2021-2026년간 6.15%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2026년까지 131억 1,951만 달러에 달할 것으로 예상됩니다.

팬데믹 기간에 갑상선 질환을 앓는 사람들은 COVID­19에 감염하기 쉽다는 사실이 많은 조사 연구에 의해 입증되었기 때문에 갑상선 호르몬 수준을 체크하고 관리하기 위해서 전세계적으로 다양한 내분비 검사가 상당히 필요해졌습니다. 2021년 1월의 조사 연구 'COVID-19 환자 50명의 갑상선 기능 분석 : 후향성 연구'에 의하면 이 조사 결과는 COVID-19가 심각해지면 TSH 및 TT3 수준이 하락하는 것을 통계적 유의성을 가지고 나타내 보였습니다. TSH 및 TT3 수준 감소 정도는 질환의 중증도와 상관관계가 있었습니다. 따라서, 혈청 TSH와 TT3 수준의 변화는 COVID-19 경과의 중요한 징후입니다.

내분비 질환의 확산과 진단 기술의 발전이 시장 성장 주요인이 되고 있습니다. 전세계적인 조기진단과 치료에 관한 의식 고양, 고령 인구 증가는 시장 성장을 지지할 것으로 예상됩니다. 내분비 검사는 내분비선에서 분비되는 호르몬 수준을 측정하고, 비만, 당뇨병, 갑상선 질환 등 다양한 질병을 진단하는 것을 가리킵니다. 2019년 국제연합에 의하면, 당뇨병 성인 환자는 약 4억 6,300만명으로, 2045년까지는 7억명까지 증가할 것으로 예측됩니다.

세계보건기구에 의하면 비만 유병률은 1975년 수준에 비해 2016년에 3배가 되었습니다. 18세 이상 약 19억명의 성인이 과체중이었습니다. 이 중 약 6억 5,000만명이 비만이었습니다. 이러한 수치는 성인의 39%와 13%가 과체중 또는 비만인 것으로 해석됩니다. 2019년에는 5세 미만 약 3,800만명이 과체중이거나 비만이었습니다. 알코올 섭취는 다양한 내분비 질환 및 장애의 가장 큰 위험요소 중 하나입니다. 전세계적으로 고소득국가가 알코올 소비량이 가장 많은 국가입니다. 많은 알코올 섭취 또한 질병 부담의 주요인 중 하나입니다. 내분비 검사 도구 수요가 높기 때문에 시장 기업은 제품 개발과 새로운 발매에도 초점을 맞추고 있습니다. 예를 들면 2018년 10월 DRG Diagnostics는 인간 혈청에서 유리 티록신을 직접 정량적으로 측정하기 위해 Free T4 ELISA 검사 키트를 발매했습니다.

전세계 많은 국가에서의 당뇨병, 갑상선 장애 유병률 증가가 시장 성장을 한층 더 가속시킬 것으로 예상됩니다. 그러나, 검사 기술 개발비가 높기 때문에 예측기간 중 시장 성장을 방해할 수 있을 것으로 예상됩니다.

세계의 내분비 검사(Endocrine Testing) 시장을 조사했으며, 시장 개요, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, COVID-19의 영향, 검사·기술·최종사용자·지역별 시장 규모 추이와 예측, 경쟁 구도, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 시장 역학

  • 시장 개요
  • 시장 성장 촉진요인
    • 내분비 질환 유병률 증가와 고령자 인구 증가
    • 제품 기술의 발전
  • 시장 성장 억제요인
    • 높은 비용의 첨단 내분비 검사 장비
    • 후진국 및 신흥국가에서의 인식 결여
  • Porter의 산업 분석

제5장 시장 세분화

  • 검사별
    • 갑상선 검사
    • 인슐린 검사
    • 인간융모 성선자극호르몬 검사
    • 프로락틴 검사
    • 황체 형성 호르몬 검사
    • 프로게스테론 검사
    • 기타
  • 기술별
    • 면역분석법
    • 텐덤질량분석
    • 센서 기술
    • 기타
  • 최종사용자별
    • 병원
    • 임상검사실
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • AB Sciex
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Biomedical Technologies
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • Ortho Clinical Diagnostics
    • Qiagen NV
    • Quest Diagnostics
    • Siemens Healthineers AG
    • Thermo Fisher Scientific

제7장 시장 기회와 동향

LSH 21.06.09

The endocrine testing market was valued at USD 9,170.62 million in 2020 and is expected to reach USD 13,119.51 million by 2026, registering a CAGR of 6.15% during the forecast period.

During the Pandemic, many research studies have been demonstrated that people with thyroid disorders are more prone to the COVID 19 infection, thus creating a significant demand for various endocrine tests globally in order to check and manage the thyroid hormone levels. As per the January 2021 research study titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study" , the results of the study demonstrated that the more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance. The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. Hence, the changes in serum TSH and TT3 levels are the important manifestations of the courses of COVID-19.

The growing prevalence of endocrine disorders and advancements in diagnostic technologies are primarily driving the market growth. Furthermore, the growing older population coupled with rising awareness about early diagnosis and treatment around the world is anticipated to boost the market growth. Endocrine testing refers to the measuring of levels of hormones secreted by the endocrine glands and diagnosis of various disorders such as obesity, diabetes, thyroid disease, and others. According to the International Federation in 2019, Diabetes approximately 463 million adults were living with diabetes and by 2045 it will rise to 700 million.

According to the World Health Organization, the prevalence of obesity had tripled in 2016, compared to the levels in 1975. About 1.9 billion adults, aged 18 years or above, were overweight. Of these, about 650 million were obese. These numbers roughly translate to 39% and 13% of the adults as overweight and obese, respectively. About 38 million children under the age of five were overweight or obese in 2019. In addition, alcohol consumption is one of the largest risk factors for various endocrine diseases and disabilities. Globally, high-income countries of the developed region have the highest alcohol consumption. This high consumption of alcohol is also serving as one of the major factors for the burden of the disease. Owing to the large demand for endocrine testing tools the market players are also focusing on product development and novel launches. For instance. in October 2018, DRG Diagnostics launched Free T4 ELISA test kits, The Free T4 ELISA Assay Kit is intended for the direct quantitative determination of free thyroxine in human serum.

The growing prevalence of diabetes, thyroid disorders in many of the countries around the globe is anticipated to further fuel the market growth. However, the high cost for the development of testing technologies is expected to impede market growth over the forecast period.

Key Market Trends

Thyroid Stimulating Hormone Testing (TSH) Anticipated to have Lucrative Growth

Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and stimulates the thyroid gland to produce thyroxine and triiodothyronine which helps in metabolism. TSH testing used to measure thyroid level. The burden of thyroid disorders is increasing across the globe. For instance, as per the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease in 2019. It was estimated that more than 12 % of the U.S. population is anticipated to develop a thyroid condition during their lifetime. The major risk factors for thyroid-associated disorders are smoking, alcohol, and tobacco consumption. As per November 2019 study conducted by researchers from the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, the results of the study demonstrated that Cigarette smoking is associated with a moderately higher level of FT4 and FT3, and lower TSH levels, which suggest partly opposing effects of alcohol consumption.

TSH measurement has recently gained a lot of importance in thyroid function testing mainly due to the technological developments in these tests facilitating cost-effective disease screening. TSH has also introduced new definitions of subclinical hypothyroidism or hyperthyroidism, along with delivering biochemical treatment targets. Furthermore, advancements in product technologies coupled with the growing affordability for healthcare is fueling the market growth. Mass spectroscopy is now used along with liquid chromatography for accurate results. This is believed to fuel market growth over the forecast period.

North America is Anticipated to Have Significant Share

North America is anticipated to have a significant share owing to the factors such as well-established healthcare infrastructure, high prevalence of obesity, advancements in diagnostic technologies, and new product launches. The less physical activity and growing prevalence of thyroid disorders are anticipated to fuel the market growth.

According to Health and Human Services (HHS), only less than 5% of adults participate in the 30 minutes of physical activity each day in the United States. More than 80% of adults do not meet the required guidelines for muscle strengthening and aerobic activities. This is leading to the consequences such as an imbalance of hormones due to obesity and diseases or conditions associated with the thyroid which is augmenting the demand for thyroid testing services. According to the American Cancer Society, it was estimated that about 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) and about 2,200 deaths from thyroid cancer (1,050 men and 1,150 women) will be reported in the United States in 2021.

North America is likely to witness major growth in the coming years, owing to several initiatives, such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research work on thyroid hormone function, cost-effective methods to detect thyroid cancer, promising research on Graves' disease, which is likely to further lead to improved prognosis, and new preventive treatments of thyroid diseases.

In mexico the growth is attributed to the rising prevalence of the disorders coupled with innovative product launches. For instance, in 2018, MedTech pioneer Proteomics International Laboratories Ltd launched of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD" in Mexican Market. Hence, owing to the above-mentioned factors, the market studied is believed to grow over the forecast period in this region.

Competitive Landscape

Global endocrine testing market is moderately competitive and there are several local as well as international companies in this market. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMerieux SA, F. Hoffmann-La Roche Ltd and Siemens AG among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Endocrine Disorders and Increasing Geriatric Population
    • 4.2.2 Advancements in Product Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Advanced Endocrine Testing Devices
    • 4.3.2 Lack of Awareness in Underdeveloped and Developing Countries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test
    • 5.1.1 Thyroid Test
    • 5.1.2 Insulin Test
    • 5.1.3 Human Chorionic Gonadotropin Test
    • 5.1.4 Prolactin Test
    • 5.1.5 Luteinizing Hormone Test
    • 5.1.6 Progesterone Test
    • 5.1.7 Others
  • 5.2 By Technology
    • 5.2.1 Immunoassay
    • 5.2.2 Tandem Mass Spectroscopy
    • 5.2.3 Sensor Technology
    • 5.2.4 Others
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Clincal Laboratories
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AB Sciex
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Agilent Technologies, Inc.
    • 6.1.4 Biomedical Technologies
    • 6.1.5 bioMerieux SA
    • 6.1.6 Bio-Rad Laboratories, Inc.
    • 6.1.7 Danaher Corporation
    • 6.1.8 DiaSorin S.p.A.
    • 6.1.9 F. Hoffmann-La Roche Ltd
    • 6.1.10 Hologic Inc.
    • 6.1.11 Ortho Clinical Diagnostics
    • 6.1.12 Qiagen N.V.
    • 6.1.13 Quest Diagnostics
    • 6.1.14 Siemens Healthineers AG
    • 6.1.15 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q